Literature DB >> 28011966

Performance of real-time PCR Xpert ®MTB/RIF in diagnosing extrapulmonary tuberculosis.

Ester Mazzola1, Marco Arosio2, Alice Nava1, Diana Fanti1, Giovanni Gesu1, Claudio Farina2.   

Abstract

The real time PCR Xpert ® MTB/RIF is fundamental for rapid diagnosis in paucibacillary respiratory samples and for the detection of multidrug-resistant TB cases. This paper aimed to determine its performance on different extrapulmonary samples. We determined sensitivity, specificity, positive and negative predictive value on respiratory and non-respiratory samples collected from January 2010 to June 2014. The protocol for the Xpert ® MTB/RIF PCR suggested by Cepheid was strictly followed for all specimens. In 12257 respiratory samples we observed a sensitivity of 87.1% and a specificity of 99.9%. There were 2818 extrapulmonary specimens, of which 250 were followed by a positive culture for Mycobacterium tuberculosis complex, whereas 72 samples were culture-negative: tuberculosis was clinically confirmed in 71 of them and was excluded for one sample. The sensitivity of the test on urine, pus and CSF samples was 88.2%, 95.6% and 100% respectively. In contrast, the sensitivity of gastric aspirates and biopsies was 81.8% and 83.6% respectively, whereas results of total cavitary fluids were significantly worse than expected (53.7% sensitivity). Our experience shows that Xpert MTB/RIF assay is an accurate, sensitive, and specific test for the rapid detection of pulmonary and extra-pulmonary TB with the only exception of cavitary fluids.

Entities:  

Mesh:

Year:  2016        PMID: 28011966

Source DB:  PubMed          Journal:  Infez Med        ISSN: 1124-9390


  8 in total

1.  Diagnostic accuracy of Xpert MTB/RIF for tuberculous meningitis: systematic review and meta-analysis.

Authors:  Adrian V Hernandez; Laryssa de Laurentis; Isadora Souza; Marcelo Pessanha; Priyaleela Thota; Yuani M Roman; Joshuan Barboza-Meca; David R Boulware; Jose E Vidal
Journal:  Trop Med Int Health       Date:  2020-11-30       Impact factor: 2.622

2.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

3.  Xpert MTB/RIF Ultra versus Xpert MTB/RIF for diagnosis of tuberculous pleural effusion: A systematic review and comparative meta-analysis.

Authors:  Ashutosh Nath Aggarwal; Ritesh Agarwal; Sahajal Dhooria; Kuruswamy Thurai Prasad; Inderpaul Singh Sehgal; Valliappan Muthu
Journal:  PLoS One       Date:  2022-07-11       Impact factor: 3.752

Review 4.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

Review 5.  Use of Digital Technology to Enhance Tuberculosis Control: Scoping Review.

Authors:  Yejin Lee; Mario C Raviglione; Antoine Flahault
Journal:  J Med Internet Res       Date:  2020-02-13       Impact factor: 5.428

6.  Application value of tissue tuberculosis antigen combined with Xpert MTB/RIF detection in differential diagnoses of intestinal tuberculosis and Crohn's disease.

Authors:  Baoying Fei; Lin Zhou; Yu Zhang; Linhe Luo; Yuanyuan Chen
Journal:  BMC Infect Dis       Date:  2021-05-28       Impact factor: 3.090

7.  Comparison between the diagnostic validities of Xpert MTB/RIF and interferon-γ release assays for tuberculous pericarditis using pericardial tissue.

Authors:  Guocan Yu; Bo Ye; Da Chen; Fangming Zhong; Gang Chen; Jun Yang; Liliang Xu; Xudong Xu
Journal:  PLoS One       Date:  2017-12-06       Impact factor: 3.240

8.  The clinical diagnostic value of Xpert MTB/RIF for the detection of Mycobacterium tuberculosis in gastric aspirates.

Authors:  Hong-Kun Tan; Shu-Jin Fan; Yu-Cheng Xu; Jiong-Jiong Zhou; Yuan-Zhi Chen; Tian-Ao Xie; Zhi-Yong Pan; Yong Xia; Xu-Guang Guo
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.